- Home
- JLS vs GALT Comparison
JLS vs GALT Comparison
Compare JLS & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JLS
- GALT
- Stock Information
- Founded
- JLS 2009
- GALT 2000
- Country
- JLS United States
- GALT United States
- Employees
- JLS N/A
- GALT N/A
- Industry
- JLS Investment Managers
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- JLS Finance
- GALT Health Care
- Exchange
- JLS Nasdaq
- GALT Nasdaq
- Market Cap
- JLS 97.1M
- GALT 83.5M
- IPO Year
- JLS N/A
- GALT N/A
- Fundamental
- Price
- JLS $18.35
- GALT $2.60
- Analyst Decision
- JLS
- GALT Buy
- Analyst Count
- JLS 0
- GALT 2
- Target Price
- JLS N/A
- GALT $6.00
- AVG Volume (30 Days)
- JLS 26.6K
- GALT 1.2M
- Earning Date
- JLS 01-01-0001
- GALT 08-12-2025
- Dividend Yield
- JLS 9.33%
- GALT N/A
- EPS Growth
- JLS N/A
- GALT N/A
- EPS
- JLS N/A
- GALT N/A
- Revenue
- JLS N/A
- GALT N/A
- Revenue This Year
- JLS N/A
- GALT N/A
- Revenue Next Year
- JLS N/A
- GALT N/A
- P/E Ratio
- JLS N/A
- GALT N/A
- Revenue Growth
- JLS N/A
- GALT N/A
- 52 Week Low
- JLS $15.48
- GALT $0.73
- 52 Week High
- JLS $17.97
- GALT $3.90
- Technical
- Relative Strength Index (RSI)
- JLS 55.47
- GALT 70.66
- Support Level
- JLS $18.27
- GALT $1.28
- Resistance Level
- JLS $18.54
- GALT $1.36
- Average True Range (ATR)
- JLS 0.17
- GALT 0.33
- MACD
- JLS 0.01
- GALT 0.18
- Stochastic Oscillator
- JLS 69.35
- GALT 52.40
About JLS Nuveen Mortgage and Income Fund
Nuveen Mortgage And Income Fund is a diversified, closed-end management investment company. The fund invests at least fifty percent of its Managed Assets in MBS, including residential MBS and commercial MBS, and up to fifty percent in non-mortgage related ABS. Its investment objective to generate high current income through opportunistic investments in securitized credit.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.